Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction

Renal Insufficiency Clinical Trial

Official title:

A Randomized, Crossover Study Assessing the Single Dose Pharmacokinetics of Delayed-Release Metformin in Subjects With Renal Dysfunction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01658514
• Other study ID #: LCRM101
• Status: Completed
• Phase: Phase 2
• First received: August 1, 2012
• Last updated: November 25, 2015
• Start date: January 2014
• Est. completion date: June 2014

Study information

• Verified date: November 2015
• Source: Elcelyx Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study evaluated how a single dose of delayed-release metformin (Met DR) behaves in subjects with normal kidney function, mild kidney dysfunction, moderate kidney dysfunction, or severe kidney dysfunction. The safety and tolerability of Met DR was also examined. In addition, this study compared the behavior of a single dose of Met DR with that of extended-release metformin (Met XR) and placebo in subjects with the varying levels of kidney function described above.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 39
• Est. completion date: June 2014
• Est. primary completion date: June 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. 18 to 80 (inclusive) years old at Visit 1 (Screening)

2. Male, or female and met all of the following criteria:

• Not breastfeeding

• Negative pregnancy test result at Visit 1 (Screening) (not applicable to postmenopausal or surgically sterile females)

• Surgically sterile, postmenopausal, or if of childbearing potential, practiced and was willing to continue to practice appropriate birth control during the entire duration of the study

• Body weight of =45 kg

3. Body mass index (BMI) of 18.0 to 40.0 kg/m² (inclusive) at Visit 1 (Screening)

4. Had type 2 diabetes mellitus and an HbA1c =10.0%

5. Had a physical examination with no clinically significant abnormalities as judged by the investigator

6. Estimated glomerular filtration rate (eGFR) =15 mL/min/1.73 m² based on the Modification of Diet in Renal Disease (MDRD) equation

7. Ability to understand and willingness to adhere to protocol requirements

Exclusion Criteria:

1. Had End Stage Renal Disease requiring dialysis or severe renal dysfunction with eGFR <15 mL/min/1.73 m²

2. Was on dialysis or had been on dialysis within 12 months of Visit 1 (Screening)

3. Had received or planned to receive any iodinated contrast dye within 1 week prior to Visit 1 (Screening) or after study medication administration

4. Was taking or had taken within 1 week of Visit 1 cationic drugs that are eliminated by renal tubular secretion (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin)

5. Had a clinically significant medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions:

• Hepatic disease

• Gastrointestinal disease

• Endocrine disorder (type 2 diabetes mellitus was allowed)

• Cardiovascular disease

• Central nervous system diseases

• Psychiatric or neurological disorders

• Organ transplantation

• Chronic or acute infection

• Orthostatic hypotension, fainting spells or blackouts

• Allergy or hypersensitivity

6. Had any chronic disease requiring medication that had been adjusted in the past 14 days (subjects could take acute intermittent over-the-counter medications such as Tylenol, if needed)

7. Had major surgery of any kind within 6 months of Visit 1 (Screening)

8. Had a clinically significant finding of an electrocardiogram (ECG) as assessed by the investigator at Visit 1 (Screening)

9. Had clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormalities, other than those related to diabetes or renal disease and other stable diseases, judged by the investigator to be clinically significant at Visit 1 (Screening)

10. Had a hemoglobin result <8 g/dL or a level indicating severe anemia of renal origin

11. Had a physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study

12. Had received Byetta® or short-acting insulin within 3 days of Visit 1 (Screening)

13. Had received metformin within 4 weeks of Visit 1 (Screening)

14. Had any drug treatment that affects gastrointestinal motility or gastric pH (prescription or over-the-counter), including any antacids or medications such as Rolaids or Pepcid, within 2 days of Visit 2

15. Abused drugs or alcohol or had a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures

16. Smoked more than 10 cigarettes, 3 cigars, or 3 pipes per day

17. Had donated blood within 2 months of Visit 1 (Screening) or was planning to donate blood during the study

18. Had received any investigational drug within one month (or seven half-lives of the investigational drug, whichever was greater) of Visit 1 (Screening)

19. Had known allergies or hypersensitivity to any component of study treatment

20. Was employed by Elcelyx Therapeutics, Inc (that is an employee, temporary contract worker, or designee of the company)

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Renal Insufficiency

Intervention

Drug:
• Met DR
metformin delayed-release tablets
• Met XR
metformin extended-release tablets
• Placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Elcelyx Therapeutics, Inc.

References & Publications (2)

Bakris GL, Mudaliar, S, Kim T, Burns C, Skare S, Baron A, Fineman M. Effects of New Metformin Formulation in Stage 3 and 4 CKD: A Pilot Study. J Am Soc Nephrol. 2014; 25:549A.

DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: Current perspectives on causes and risk. Metabolism. 2016 Feb;65(2):20-9. doi: 10.1016/j.metabol.2015.10.014. Epub 2015 Oct 9. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUC (0-t) of Plasma Metformin	AUC (0-t) = Area under the curve from the time of dosing (0 h) to the time of the last quantifiable concentration following dose administration	from the time of dosing (0 h) to 72 hours postdose	No
Primary	Cmax of Plasma Metformin	Cmax = Maximum concentration from the time of dosing (0 h) to the time of the last quantifiable metformin concentration following dose administration	from the time of dosing (0 h) to 72 hours postdose	No
Primary	Correlation of Placebo-adjusted Change From Pre-dose Value in Lactate Versus Metformin Concentration	To determine the exposure-response relationship of metformin and plasma lactate concentrations	from the time of dosing (0 h) to 24 hours postdose	Yes